Flexion Therapeutics (FLXN) Stock Price Down 5%

Flexion Therapeutics Inc (NASDAQ:FLXN) was down 5% during trading on Friday . The company traded as low as $14.89 and last traded at $14.96. Approximately 1,812,275 shares changed hands during mid-day trading, an increase of 188% from the average daily volume of 628,971 shares. The stock had previously closed at $15.75.

A number of equities research analysts recently commented on FLXN shares. BidaskClub upgraded Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, October 12th. Zacks Investment Research upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Friday, August 10th. Wells Fargo & Co set a $39.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 22nd. Finally, ValuEngine upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Flexion Therapeutics has a consensus rating of “Buy” and an average target price of $34.80.

The company has a quick ratio of 8.74, a current ratio of 8.88 and a debt-to-equity ratio of 1.02. The stock has a market capitalization of $595.86 million, a P/E ratio of -3.60 and a beta of 1.18.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.09. Flexion Therapeutics had a negative return on equity of 88.21% and a negative net margin of 1,346.87%. The business had revenue of $6.99 million for the quarter, compared to analyst estimates of $5.93 million. Analysts forecast that Flexion Therapeutics Inc will post -4.63 earnings per share for the current year.

In other Flexion Therapeutics news, CFO David Arkowitz bought 4,000 shares of Flexion Therapeutics stock in a transaction dated Friday, November 9th. The stock was acquired at an average cost of $16.56 per share, with a total value of $66,240.00. Following the purchase, the chief financial officer now directly owns 48,250 shares in the company, valued at approximately $799,020. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael D. Clayman bought 5,000 shares of Flexion Therapeutics stock in a transaction dated Friday, November 9th. The shares were acquired at an average cost of $17.10 per share, with a total value of $85,500.00. Following the completion of the purchase, the insider now owns 83,295 shares in the company, valued at $1,424,344.50. The disclosure for this purchase can be found here. Corporate insiders own 14.59% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System raised its stake in shares of Flexion Therapeutics by 22.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock worth $411,000 after buying an additional 2,960 shares during the period. Redmile Group LLC raised its stake in shares of Flexion Therapeutics by 33.5% during the 2nd quarter. Redmile Group LLC now owns 13,260 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 3,330 shares during the period. Alps Advisors Inc. raised its stake in shares of Flexion Therapeutics by 8.5% during the 2nd quarter. Alps Advisors Inc. now owns 54,622 shares of the specialty pharmaceutical company’s stock worth $1,412,000 after buying an additional 4,272 shares during the period. Dupont Capital Management Corp raised its stake in shares of Flexion Therapeutics by 15.9% during the 3rd quarter. Dupont Capital Management Corp now owns 31,688 shares of the specialty pharmaceutical company’s stock worth $593,000 after buying an additional 4,354 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Flexion Therapeutics by 3.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 179,658 shares of the specialty pharmaceutical company’s stock worth $4,645,000 after buying an additional 5,257 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Flexion Therapeutics (FLXN) Stock Price Down 5%” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/12/07/flexion-therapeutics-flxn-stock-price-down-5.html.

Flexion Therapeutics Company Profile (NASDAQ:FLXN)

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Story: What Is An Exchange-Traded Fund (ETF)?

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply